CRISM Therapeutics (LON:CRTX) Releases Quarterly Earnings Results

CRISM Therapeutics (LON:CRTX) announced its quarterly earnings results on Friday. The company reported GBX (0.05) EPS for the quarter, Digital Look Earnings reports.

CRISM Therapeutics Trading Down 5.0%

CRTX traded down GBX 0.50 on Friday, reaching GBX 9.50. The stock had a trading volume of 258,541 shares, compared to its average volume of 291,726. The company has a market capitalization of £5.15 million, a price-to-earnings ratio of -2.16 and a beta of 0.58. CRISM Therapeutics has a fifty-two week low of GBX 8 and a fifty-two week high of GBX 23. The firm has a 50-day moving average of GBX 11.50 and a 200-day moving average of GBX 11.67.

About CRISM Therapeutics

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.